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 Abstract 
 Background: The usefulness of S100 as a prognostic 
marker and aid in follow-up care in patients with malig-
nant melanoma as well as in individuals with various 
neurological pathologies is well known. The aim of 
this study was to investigate its release and clinical rel-
evance in benign and malignant disorders beyond these 
indications to elucidate tumor and organ specificity of 
S100. 
 Methods: S100 levels were studied in serum samples of 
1856 untreated patients, among them 59 healthy individu-
als, 358 patients with benign disorders, and 1439 patients 
with malignant tumors. 
 Results: Healthy individuals had low S100 levels reach-
ing a median of 0.041 ng/mL and 95th and 100th percen-
tiles of 0.096 ng/mL and 0.144 ng/mL, respectively. The 
medians of patient groups with benign diseases ranged 
from 0.030 to 0.057 ng/mL, patients with malignant dis-
eases from 0.020 to 0.059 ng/mL, and thus were compa-
rable to healthy individuals. Only 2 % of patients with 
benign diseases, mainly suffering from infectious, auto-
immune, or benign gastrointestinal diseases, and 1 % of 
patients with malignant diseases showed slightly higher 
values than healthy individuals, in most cases up to 
0.5 ng/mL. 
 Conclusions : In contrast to many other oncological bio-
markers, S100 is only rarely released in elevated levels 
from most benign and malignant diseases apart from 
malignant melanoma and neurological diseases, result-
ing in superior organ and tumor specificity. As potentially 
influencing factors, severe infectious diseases have to be 
considered. 
 Keywords:  cancer;  diagnosis;  serum;  S100. 
 Zusammenfassung 
 Hintergrund: S100 ist als n ü tzlicher Biomarker f ü r die 
Prognoseasch ä tzung und die Verlaufsbeobachtung bei 
Patienten mit malignem Melanom und in Patienten mit ver-
schiedenen neurologischen Erkrankungen anerkannt. Das 
Ziel dieser Studie war, die Freisetzung und klinische Rele-
vanz von S100 bei anderen benignen and malignen Erkran-
kungen jenseits dieser Indikationen zu untersuchen, um 
die Tumor- und Organspezifit ä t von S100 zu bewerten. 
 Methoden: S100-Konzentrationen wurden in Serumpro-
ben von 1856 unbehandelten Patienten ermittelt, darunter 
59 gesunde Personen, 358 Patienten mit benignen Erkran-
kungen und 1439 Patienten mit malignen Tumoren. 
 Ergebnisse: Gesunde Personen hatten niedrige S100 
Serumwerte, die einen Median von 0.041 ng/mL, eine 95. 
Perzentile von 0.096 ng/mL und ein Maximum von 0.144 
ng/mL erreichten. Die Mediane der Patientengruppen lagen 
bei benignen Erkrankungen zwischen 0.030 und 0.057 
ng/mL, bei Patienten mit malignen Tumoren zwischen 
0.020 und 0.059 ng/mL  – und waren somit vergleichbar 
zu gesunden Kontrollpersonen. Lediglich 2 % der Patien-
ten mit benignen Erkrankungen, v.a. infekti ö sen, autoim-
munen oder benignen gastrointestinalen Erkrankungen, 
sowie 1 % der Patienten mit malignen Tumoren wiesen im 
Vergleich zu gesunden Personen leicht erh ö hte Werte auf  – 
in den meisten F ä llen bis 0.5 ng/mL. 
 Schlussfolgerung : Im Gegensatz zu vielen anderen onko-
logischen Biomarkern wird S100 nur selten in h ö heren 
Konzentrationen von den meisten benignen und malig-
nen Erkrankungen  – mit Ausnahme des malignen Mela-
noms und neurologischer Erkrankungen  – freigesetzt, 
was sich in einer sehr hohen Organ- und Tumorspezifit ä t 
widerspiegelt. Als m ö glicher Einflussfaktor sind schwere 
infekti ö se Erkrankungen zu ber ü cksichtigen. 
 Schl ü sselw ö rter:  Diagnose;  Krebs;  Serum;  S100. 
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 Introduction 
 S100 constitutes a thermolabile, acidic protein of 21 kDa 
molecular weight which was originally detected in the 
central nervous system of vertebrates  [1 – 3] . Its name 
derives from its biochemical properties to remain soluble 
even in 100 % ammonium sulfate at neutral pH. S100 is 
part of a multigenic family of calcium-binding proteins 
and consists of a dimer of two isomeric subunits ( α , 10.4 
kDa and  β , 10.5 kDa). It exists in the isoforms S100B ( β β ), 
S100A ( α β ), and S100A1 ( α α )  [1 – 3] . 
 S100B is localized in high concentrations in astro-
glial cells of the central nervous system; in addition, it 
is produced in lower amounts by Schwann cells of the 
peripheral nervous system, by chondrocytes, adipocytes, 
and Langerhans cells. S100A is exprimed particularly 
by malignant melanoma cells and shows a correlation 
with invasivity and tumor extent. In the central nervous 
system, S100A is present in low amounts contributing 
only 5 % to total cerebral S100 concentration. S100A1 is 
found in ceratinocytes, melanocytes, in smooth muscle 
cells, cardiomyocytes, and in the kidney  [1 – 3] . 
 Currently, 21 isoforms of the S100 family are known. 
Owing to their function as intracellular calcium recep-
tor molecules, they are involved in the regulation of the 
cell cycle at various levels such as differentiation and 
proliferation. Additionally, S100 interacts with tumor 
suppressor protein p53 and blocks its phosphorylation 
by protein kinase C. As a result, p53 is not able to main-
tain its function in regulating the cell cycle, DNA repair, 
and induction of apoptosis  [1, 2] . Furthermore, S100B is 
known to bind to the receptor for advanced glycation end 
products (RAGE) and leads among others to activation 
of astrocytes, which are involved in various neurological 
disorders  [4] . Stimulation of RAGE is further reported as a 
central mechanism of proinflammatory proteins S100A8/
A9  [5] and S100A6  [6] . Interestingly, S100B and S100A6 
subtypes bind to different extracellular RAGE domains 
and modulate cell survival and proliferation by different 
RAGE-dependent pathways  [6] . 
 In malignant melanoma, S100 is widely appreci-
ated for immunhistochemical diagnosis and is used in 
serum for differential diagnostic purposes of lymph node 
positivity or metastatic disease  [1, 2, 7 – 9] . In addition, 
it has been proposed for detection of metastatic uveal 
melanoma  [10, 11] . Furthermore, it is an independent 
predictive and prognostic marker and is recommended 
for progression detection in advanced stages and for the 
monitoring of systemic therapies in patients with and 
without distant metastases  [1, 2, 12 – 21] . Thereby, S100B 
has been shown to have superior prognostic information 
than lactate dehydrogenase (LDH)  [7, 16, 22, 23] and to 
be additive to melanoma inhibitory antigen (MIA)  [7, 24] . 
In addition, S100 in serum and cerebrospinal fluid is 
 valuable for the diagnosis and follow-up of neurode-
structive and neurodegenerative diseases, such as cere-
bral trauma, ischemia and infection, in cases of hypoxic 
lesions after cardiac arrest or inverventions with car-
diopulmonary bypass. Particularly after acute cerebral 
events, the determination of S100 in serum is appropri-
ate for the estimation of the disintegration of the blood-
brain barrier  [3, 25, 26] . 
 Most concurrent commercially available S100 assays 
use mono- or polyclonal antibodies directed against the 
 β -subunit of S100 and detect the isoforms S100A and 
S100B  [27 – 29] . However, some assays also enable more 
detailed characterization of S100 subtypes  [17] . Compari-
sons between different methods for the quantification of 
S100 revealed good assay characteristics for automatized 
assays, however, often only moderate to poor correlations 
with considerable slopes, particularly to manual assays 
 [27 – 29] . In the present study, S100 values were assessed 
by the automatized Elecsys  ®  S100 assay (Roche Diagnos-
tics, Mannheim, Germany), which has shown excellent 
methodical performance in earlier studies  [28, 29] . 
 In the past tumor markers were often only validated 
for diagnosis, prognosis, and/or therapy monitoring in 
those tumor entities for which the parameter revealed a 
particular sensitivity, and the influence of other benign 
and malignant diseases on the release of this tumor 
marker was not considered. However, because these inter-
fering factors would be of high relevance, particularly for 
the interpretation of kinetic observations during or after 
therapy, we evaluated this S100 assay according to the rec-
ommendations of the European Group on Tumor Markers 
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(EGTM)  [30] beyond the classical applications to elucidate 
its tumor and organ specificity. 
 Patients and methods 
 In total, we investigated serum samples of 1856 individuals 
including 59 healthy persons, 1439 patients with various 
cancer diseases (lung, colorectal, breast, ovarian, cervix-
uterus, stomach, hepatocellular, prostate, pancreatic, 
bladder, and others), and 358 with various benign dis-
eases relevant for differential diagnosis (gastrointestinal, 
gynecological, lung, breast, urological, prostate, autoim-
mune, infections, and others) (Table  1 ). All samples were 
obtained at the time of acute disease and before the start 
of the recommended therapy  – in cancer patients mostly 
before surgery. 
 For determination of S100, we used the Elecsys  ®  S100 
assay working with two monoclonal mouse antibod-
ies directed against the S100  β -subunit. In this system, 
20  μ L of the patient sample is incubated with a bioti-
nylated S100 antibody and a ruthenium-labeled S100 
antibody forming a sandwich complex. After adding 
streptavidin-coated microparticles, this complex binds 
to the solid phase, which is subsequently transferred to 
the detection cell. By magnetic effects, the microparti-
cles are fixed on the surface of an electrode, and after a 
 Table 1   Distribution of S100 values in healthy persons and patients with various benign and malignant diseases (number, median, range, 
95 % percentile). 




95 % Percentile, 
ng/mL
Healthy individuals 59 0.041 0.001 – 0.144 0.096
Benign gastrointestinal disease 50 0.051 0.015 – 0.223 0.161
Benign gynecological disease 50 0.057 0.028 – 0.105 0.100
Benign lung disease 50 0.050 0.016 – 0.186 0.147
Benign breast disease 50 0.037 0.010 – 0.084 0.072
Benign urological disease 52 0.036 0.001 – 0.115 0.088
Benign prostate hyperplasia 29 0.045 0.011 – 0.110 0.102
Autoimmune disease 20 0.030 0.001 – 0.388 0.373
Infections 30 0.052 0.018 – 1.960 1.069
Lung cancer 472 0.020 0.001 – 0.301 0.062
Colorectal cancer 682 0.022 0.001 – 0.534 0.064
Breast cancer 50 0.049 0.003 – 0.193 0.163
Ovarian cancer 50 0.042 0.006 – 0.106 0.091
Cervical cancer 27 0.032 0.002 – 0.236 0.187
Gastric cancer 30 0.035 0.001 – 0.373 0.350
Hepatocellular cancer 30 0.059 0.022 – 0.462 0.320
Prostate cancer 29 0.044 0.013 – 0.256 0.184
Pancreatic cancer 30 0.046 0.006 – 0.171 0.129
Bladder cancer 30 0.036 0.001 – 0.156 0.156
 Table 2   Sensitivities of detecting cancer disease at a 95 % specific-
ity to patients with the relevant benign comparison group. 
Group Sensitivity,  % Cut-off value, ng/mL
Lung cancer 2 0.096
Colorectal cancer 1 0.121
Breast cancer 24 0.068
Ovarian cancer 2 0.092
Cervical cancer 7 0.094
Gastric cancer 10 0.121
Hepatocellular cancer 10 0.121
Prostate cancer 6 0.095
Pancreatic cancer 3 0.121
Bladder cancer 10 0.072
washing step they can be quantified by determination of 
chemiluminescence emission by a photomultiplier. By 
use of a two-point calibration and a master curve, the 
concentration of S100 in the sample is calculated. The 
lower detection limit is indicated at an analytical sen-
sitivity level of  < 0.005 ng/mL, the functional sensitivity 
is  < 0.02 ng/mL. 
 Distribution of the values is shown by dot plots and 
statistical tables. Sensitivities for the various malignant 
diseases were calculated using the 95 % percentile of 
the relevant benign comparison group as a cut-off value 
(Table  2 ). 
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 Figure 2   Distribution of S100 values in healthy persons and patients with various benign diseases. 
 Results 
 S100 values in serum of healthy persons were found to 
be very low with a median of 0.041 ng/mL, a 95 % per-
centile of 0.096 ng/mL, and a range between  < 0.005 ng/
mL and 0.144 ng/mL (Figure  1 , Table 1). In patients with 
benign disorders, S100 values were comparable with 
medians between 0.030 ng/mL and 0.052 ng/mL (Figure 
 2 , Table 1). The ranges of S100 values were in most 
disorders between  < 0.005 ng/mL and 0.25 ng/mL. Only 
some patients with autoimmune diseases reached values 
up to 0.40 ng/mL; and most importantly, in single cases of 
patients with acute infections values were observed up to 
1.96 ng/mL. Patients with various malignant diseases did 
not show markedly elevated levels of S100 (Figure  3 , Table 
1). The medians were for most cancers in the range of benign 
diseases (0.030 – 0.059 ng/mL). The highest S100 values 
were observed in colorectal cancer with 0.534 ng/mL, 
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and in hepatocellular cancer with 0.462 ng/mL. Concern-
ing the sensitivity for cancer detection, cut-off values were 
defined at the 95 % percentile of the relevant benign com-
parison group. For most tumors investigated, the sensitivi-
ties ranged up to 10 % . Only in breast cancer, a sensitivity 
of 24 % was observed (Table 2). 
 Discussion 
 Several studies have shown the value of S100 in diagno-
sis, prognosis, and therapy monitoring of malignant mela-
noma. Expression and release of S100 were observed to be 
elevated in serum of patients with malignant melanoma 
with clear correlation to stage. Whereas during stages I and 
II, the median of serum S100 values was comparable with 
the median of healthy individuals, stage III and particularly 
stage IV disease were associated significantly with higher 
S100 levels  [1, 31 – 36] . In one study  including advanced 
stages of melanoma, a median of 6.25 ng/mL and maximum 
values  > 90 ng/mL were reported  [31] . Concerning the site of 
distant metastases, liver and bone metastases were related 
to higher S100 values than cutaneous lesions  [33, 36] . 
 In addition to diagnostic aspects, S100 was found to 
be a valuable prognostic marker concerning progression-
free interval and overall survival  [18 – 23, 35 – 40] . In 670 
high-risk surgically resected melanoma patients, high 
baseline and increasing S100 values were independent 
prognostic markers  [20] . Also in stages IIb and III mela-
noma patients, S100 was of high prognostic value  [19, 37] . 
In stage IV, S100 strongly correlated with LDH  [36] and had 
superior prognostic value than LDH in multiple settings 
 [7, 16, 22, 23] . The clinical relevance of S100 as a prognos-
tic marker in melanoma patients independent from TNM 
stage was confirmed by a recent meta-analysis on more 
than 3000 patients  [18] , which emphasized its prognostic 
role particularly for stage I – III patients. 
 Serial determination of S100 proved to be useful for lon-
gitudinal observations during or after treatment. Particularly 
in stage III, progression was detected with a lead time of 
5 to 23 weeks prior to the appearance of macroscopic meta-
stases  [41 – 43] . In stage IV, S100 increases were correlated 
with insufficient responses to systemic therapy. In some 
cases, a see-saw pattern was observed with strong decreases 
after every application followed by increases until the next 
treatment date  [32] . By contrast, efficient therapy resulted in 
significant decreases of S100 to low levels at the detection 
limit  [12, 42 – 44] . Recently, S100 was also found to be useful 
to assess response to bevacizumab induction treatment in 
stage III melanoma patients  [13] . In a follow-up of melanoma 
patients, S100 showed to be valuable for early detection of 
progression as an adjunct to positron emission computed 

























































































 Figure 3   Distribution of S100 values in patients with various malignant tumors. 
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 Similar to many other biochemical blood parameters, 
S100 concentrations in serum might be influenced by 
pathophysiological conditions that affect the expression, 
release, or metabolism of S100 in circulation. These disor-
ders include various benign and malignant diseases that 
would be crucial to identify when S100 levels in serum 
have to be interpreted, particularly for therapy monitoring 
or detection of recurrent disease in melanoma patients. 
For example, earlier studies have shown that elevated 
serum concentrations of S100 are present in patients after 
trauma, cerebral ischemia and infections, hypoxic lesions 
after cardiac arrest, and after surgical heart interventions 
with cardiopulmonary bypasses being involved  [3, 25, 
45 – 48] . 
 To elucidate the tumor and organ specificity of S100 
for malignant melanoma, we investigated in detail various 
benign diseases that are known to potentially alter the 
concentrations of several tumor markers in serum such as 
benign gastrointestinal, gynecological, lung, breast, and 
urological diseases, benign prostate hyperplasia, as well 
as autoimmune and infectious diseases, including also 
those with renal and hepatic failure  [49] . In addition, we 
addressed various malignant tumor diseases that might 
confound S100 levels in serum and be relevant for differ-
ential diagnosis of suspicious lesions. 
 In healthy persons, most studies have found only low 
serum S100 concentrations with a median of 0.04 ng/mL 
and a 95 % percentile of approximately 0.1 ng/mL, which is 
in concordance with our results. Differences according to 
gender and age were not observed  [50] . However, benign 
disorders have been investigated in detail only by one 
group using a luminimetric S100 assay. Corresponding 
with our findings, S100 levels in many benign  pulmonary, 
gynecological, urological, gastrointestinal, and autoim-
mune diseases were reported to be in the range of healthy 
persons. Only liver cirrhosis and renal failure was related 
to slightly higher S100 values up to 0.7 ng/mL; in addi-
tion, one patient with renal failure exhibited strongly 
elevated levels of 4.75 ng/mL  [31] . In our evaluation, we 
could not confirm these findings. However, we found that 
in some cases of bacterial infections S100 values were up 
to 1.96  ng/mL. Particularly, in polytraumatic patients at 
intensive care units and those being at risk of septic com-
plications, these results have to be considered for differ-
ential diagnosis. 
 As expected, most malignant disorders did not lead 
to substantial elevations of serum S100. No patients with 
breast, ovarian, cervix, gastric, liver, pancreatic, bladder, 
and prostate cancers showed higher S100 values. Only 
single cases were observed with concentrations up to 
0.53 ng/mL. These observations confirm that, unlike many 
other oncological biomarkers, high serum concentrations 
of S100 ( > 0.5 ng/mL) have a high specificity for malignant 
melanoma, which is relevant for the differential diagno-
sis of a cancer of unknown primary (CUP), particularly 
if suspicious cerebral, hepatic, or pulmonary lesions are 
present. Owing to its high tumor and organ specificity, 
S100 is, further, a valuable marker for therapy monitoring 
and detection of recurrent disease in melanoma patients. 
However, potentially influencing factors have to be con-
sidered for interpretation of S100 kinetics. 
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